Innate Pharma announces Yannis Morel broadens remit to COO

Innate Pharma announced that it has appointed two new executive board members. Arvind Sood, executive VP, president of US Operations, Sonia Quaratino, EVP, chief medical officer are thus joining Herve Brailly, interim CEO and Yannis Morel, EVP, COO. Yannis Morel, current EVP, business development and product portfolio Strategy and member of the executive board broadens his remit to become EVP, COO extending his operational responsibility to the management of research and early development, working with Innate Pharma chief scientific officer Eric Vivier, and chief development officer, Nicola Beltraminelli. Sonia Quaratino, current EVP, chief medical officer is appointed to the executive board. Quaratino joined Innate Pharma in October 2023 bringing over 25 years of experience in basic research, clinical development, and translational medicine, having worked in academia, global large pharmaceuticals, and biotech companies.